STOCK TITAN

SRX Global Provides Update on Engineered T-Cell Strategy Following Pfizer–Starna Licensing Agreement

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

SRX Global (NYSE American: SRXH) updated investors on its pending acquisition of CERo Therapeutics after Pfizer announced a separate licensing deal with Starna Therapeutics. Under a definitive purchase agreement, CERo would become a wholly owned SRX subsidiary. Neither SRX nor CERo is involved in the Pfizer–Starna deal, which carries a $330 million upfront payment. SRX said it does not view that deal as a valuation benchmark for CERo.

CERo reported seven patients dosed in the ongoing Phase 1/1b CERTAIN-T trial of CER-1236, an investigational engineered T-cell therapy for blood cancers. The seventh patient was the fourth in the second dose group. The three previously treated patients in that group had no dose-limiting toxicities during the assessment window. CERo also activated UC Davis as a trial site. The findings are preliminary and based on few patients; they do not establish safety or efficacy.

Loading...
Loading translation...
7 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Definitive purchase agreement would make CERo Therapeutics a wholly owned SRX subsidiary
  • Minor pointPhase 1/1b CERTAIN-T trial reached seven patients dosed, including four in the second dose group
  • Minor pointSecond dose group had no dose-limiting toxicities in its three previously treated patients during the assessment window
  • Minor pointJune safety update reported no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, dose-limiting toxicities or severe treatment-related adverse events during the assessment window
  • Minor pointInfused CER-1236 cells expanded after administration, as reported by CERo
2 minor points
  • Minor pointTrial eligibility broadened to include additional blood disorders beyond acute myeloid leukemia
  • Minor pointUC Davis was activated as a trial site and also serves as the primary manufacturing site for CER-1236

Negative

  • Moderate pointCERo Therapeutics acquisition remains pending
  • Minor pointCER-1236 findings are preliminary and based on a limited number of patients; they do not establish safety or efficacy

Key Figures

Upfront payment: $330 million Development and commercial milestones: Up to $2.3 billion Programs covered: 3 pre-IND in vivo CAR-T programs +2 more
Upfront payment
$330 million
Pfizer–Starna licensing agreement
Development and commercial milestones
Up to $2.3 billion
Eligible payments under the Pfizer–Starna licensing agreement
Programs covered
3 pre-IND in vivo CAR-T programs
Pfizer–Starna licensing agreement
Patients dosed
7 patients
Ongoing Phase 1/1b CERTAIN-T trial
Second-cohort dose-limiting toxicities
No dose-limiting toxicities in 3 previously treated patients
During the DLT assessment period

Historical Context

1 past event · Latest: Oct 26
1 event
  1. Oct 26

    Phase 1 trial update

    24h Move
    -2.8%

    UC Davis site activation and prior six-patient findings included no DLTs in the second cohort.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

car-t, dose-limiting toxicities, cytokine release syndrome, pharmacokinetics, +1 more
5 terms
car-t medical
"in vivo chimeric antigen receptor T-cell (“CAR-T”) programs"
CAR-T is a type of cancer therapy that reprograms a patient’s own immune cells to seek and destroy specific cancer cells, like teaching guard dogs a new scent to track intruders. It matters to investors because CAR-T treatments can command high prices, drive strong revenue for successful developers, and carry regulatory and manufacturing risks that can sharply affect a company’s valuation and long-term growth prospects.
dose-limiting toxicities medical
"no dose-limiting toxicities (“DLTs”)"
Dose-limiting toxicities are the harmful side effects seen in early clinical trials that are severe enough to stop researchers from raising a drug’s dose. Like a car’s speed limiter marking the safe top speed, DLTs define the maximum tolerable dose, and they matter to investors because they determine whether a medicine can reach effective levels, influence development timelines, costs, and regulatory chances, and thus affect a drug’s commercial prospects.
cytokine release syndrome medical
"no cytokine release syndrome"
An intense immune overreaction in which the body's defense system releases a large surge of signaling proteins, causing fever, low blood pressure, breathing trouble or organ stress; imagine the immune system's alarm going into overdrive and flooding the body with emergency responders. Investors care because this side effect can slow or block regulatory approval, increase clinical trial costs and liabilities, limit how widely a therapy can be used, and therefore affect a drug's market value and sales potential.
pharmacokinetics medical
"evaluate the safety, tolerability, pharmacokinetics"
Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.
measurable residual disease medical
"measurable residual disease (“MRD”)"
Measurable residual disease (MRD) is the tiny number of cancer cells that remain in a patient after treatment and can be detected using sensitive laboratory tests even when scans look clear. For investors, MRD matters because it's a strong early signal of how well a therapy works, can influence clinical trial success, regulatory decisions and future sales, and helps predict whether disease will come back much like spotting embers after a put-out fire.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Pfizer’s $330 million upfront commitment to three pre-IND in vivo CAR-T programs highlights pharmaceutical industry interest in next-generation engineered T-cell platforms

SRX’s pending acquisition of CERo Therapeutics provides exposure to CER-1236, a clinical-stage engineered T-cell therapy with seven patients dosed in the ongoing Phase 1/1b CERTAIN-T trial

NORTH PALM BEACH, Fla., Nov. 20, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today commented on recent industry activity in engineered T-cell therapies following the November 18, 2026 announcement by Pfizer Inc. (“Pfizer”) of an exclusive licensing agreement with Starna Therapeutics (“Starna”), and provided an update on its pending acquisition of CERo Therapeutics, the operating subsidiary of CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo Holdings” and, together with CERo Therapeutics, “CERo”), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed to engage phagocytic mechanisms.

According to Pfizer’s announcement, the agreement covers three pre-IND in vivo chimeric antigen receptor T-cell (“CAR-T”) programs focused on treating autoimmune diseases. Starna will receive an upfront payment of $330 million and is eligible to receive up to $2.3 billion in development and commercial milestone payments, as well as royalties on net sales of approved products. Pfizer also obtained rights to Starna’s technology in inflammation and immunology and in oncology. SRX and CERo are not parties to, and have no involvement in, the Pfizer–Starna agreement.

CERo’s approach differs in technology, therapeutic focus and stage of development. Its lead investigational product candidate, CER-1236, is being evaluated in patients with hematologic malignancies in the ongoing Phase 1/1b CERTAIN-T trial. CER-1236 is based on CERo’s proprietary Chimeric Engulfment Receptor T cell (“CER-T”) platform, which is designed to integrate characteristics of innate and adaptive immunity into a single therapeutic construct intended to engage multiple immune mechanisms against cancer.

“Pfizer’s agreement with Starna is a clear signal that large pharmaceutical companies continue to commit significant capital to differentiated engineered T-cell platforms, even before those programs reach the clinic,” said Kent Cunningham, Chief Executive Officer of SRX Global. “CERo’s technology and indications are different, and we do not view this transaction as a valuation benchmark for CERo. What it does reinforce is our conviction in the long-term strategic importance of this field. CER-1236 is already being evaluated in patients, and our focus remains on supporting the CERo team as it advances the CERTAIN-T trial and on working toward closing the proposed acquisition.”

On November 3, 2026, CERo announced that it had dosed the seventh patient in CERTAIN-T, the fourth patient in the trial’s second cohort. CERo reported no dose-limiting toxicities (“DLTs”) in the three previously treated second-cohort patients during the DLT assessment period, and has reported expansion of infused CER-1236 cells following administration. In its June 2026 update, CERo reported that the observed safety profile remained consistent with earlier findings of no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, DLTs or treatment-related severe adverse events during the DLT assessment window. CERo has also expanded its clinical trial sites, including the activation of the University of California, Davis, which also serves as the primary manufacturing site for CER-1236. These clinical results are preliminary, are based on a limited number of patients, and are not sufficient to establish the safety or efficacy of CER-1236.

On October 7, 2026, SRX announced that it had entered into a definitive purchase agreement under which CERo Therapeutics will become a wholly owned subsidiary of SRX Global.

About the CERTAIN-T Trial
The first-in-human, multicenter, open-label Phase 1/1b CERTAIN-T study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of CER-1236 in patients with hematologic malignancies. The study initially enrolled patients with acute myeloid leukemia (“AML”), including relapsed/refractory AML, measurable residual disease AML, and newly diagnosed TP53-mutated AML, and the protocol has since been amended to include transfusion-dependent myelodysplastic syndromes (“TD-MDS”), high-risk myelodysplastic syndromes (“HR-MDS”), and post-JAK inhibitor myelofibrosis (“MF”). Primary endpoints include safety and tolerability. Secondary endpoints include pharmacokinetics and measures of clinical response, including overall response rate (“ORR”), complete response (“CR”), composite complete response (“cCR”), and measurable residual disease (“MRD”).

About SRX Global Inc.
SRX Global is an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction operating companies, strategic assets, and technology-enabled opportunities. The Company leverages proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across multiple sectors.

About CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc. is an innovative immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering is designed to integrate characteristics of innate and adaptive immunity into a single therapeutic construct intended to engage multiple immune mechanisms against cancer. CERo refers to these engineered cells as Chimeric Engulfment Receptor T cells (“CER-T”).

The Company’s lead investigational product candidate, CER-1236, is being evaluated in hematologic malignancies.

Forward-Looking Statements
This communication contains forward-looking statements within the meaning of applicable securities laws. These statements include, without limitation, statements regarding the proposed acquisition of CERo Therapeutics by SRX Global, including its expected timing and completion and the satisfaction of closing conditions; industry interest in and investment in engineered T-cell therapies; the clinical development, safety profile, pharmacokinetic and pharmacodynamic characteristics, therapeutic potential, and future evaluation of CER-1236; the progression, design, and enrollment of the CERTAIN-T trial; planned cohort expansion and dose escalation; and SRX Global’s and CERo’s development strategy and objectives. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

Risks and uncertainties include, among others, the possibility that the proposed transaction is not completed on the anticipated timeline or at all; the failure to satisfy closing conditions; and the risks inherent in the clinical development of CER-1236, an investigational product candidate. Information in this communication regarding the Pfizer–Starna agreement is based solely on Pfizer’s public announcement, has not been independently verified by SRX, and should not be interpreted as indicating a valuation for CERo or SRX Global or the likelihood of any similar transaction. Information in this communication regarding CERo, CER-1236 and the CERTAIN-T trial is based on information provided or publicly disclosed by CERo. Prior to the closing of the proposed transaction, SRX does not control CERo and cannot guarantee CERo’s clinical, regulatory, or business outcomes.

Certain risks that could cause actual results to differ are set forth in SRX Global’s and CERo’s respective filings with the Securities and Exchange Commission, including their most recent Annual Reports on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in these filings are not exhaustive. Forward-looking statements are not guarantees of performance, and undue reliance should not be placed on such statements. SRX Global undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Company Contact
SRX Global Inc.
Kent Cunningham, Chief Executive Officer

Investor Relations Contact
KCSA Strategic Communications
Valter Pinto, Managing Director
212-896-1254
srx@kcsa.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the status of SRX Global’s acquisition of CERo Therapeutics?

SRX Global’s acquisition of CERo Therapeutics remains pending under a definitive purchase agreement. SRX announced the agreement on October 7, 2026. Under its terms, CERo Therapeutics would become a wholly owned subsidiary of SRX Global.

What did CERo report about CER-1236 in the CERTAIN-T trial?

CERo reported no dose-limiting toxicities during the assessment window in the three previously treated patients in the second dose group. The seventh patient dosed overall was the fourth in that group. CERo also reported that infused CER-1236 cells expanded after administration. The preliminary findings do not establish safety or efficacy.

What are the primary and secondary endpoints in CERo’s CERTAIN-T trial?

The primary endpoints in CERo’s CERTAIN-T trial include safety and tolerability. Secondary endpoints include how the therapy behaves in the body and measures of clinical response, including overall response rate, complete response, composite complete response, and measurable residual disease.

What milestone payments and royalties are included in the Pfizer–Starna deal discussed by SRX Global?

Starna is eligible for up to $2.3 billion in development and commercial milestone payments, plus royalties on net sales of approved products. These terms are separate from the $330 million upfront payment. Neither SRX Global nor CERo is a party to the agreement.

Keep reading